Pharmapedia

Greater use of pharmacists to treat minor illnesses could potentially save millions of dollars in health care costs, according to new research led by Washington State University. The findings also indicate a way to improve healthcare access by expanding availability of pharmacists’ clinical services including prescribing medications, amid an ongoing shortage of primary care providers.

Vinay Kumar Singh. 
Head-Formulation
Kumar Organic Products Research Centre Pvt. Ltd.,
Bengaluru
Email : formulation_krc@kopresearchcentre.net

The table below explains the new Medicines Recall and Notification classifications and the associated defect risk classification.

Medicines Recall/Notification Classification : Defect risk classification

National Patient Safety Alert (NatPSA) equivalent to Class 1 Medicines Recall : The defect presents a risk of death or disability. These alerts will be issued via CAS as National Patient Safety Alerts and will be published on the MHRA website.

For heart attack patients, treating only the coronary artery that caused the infarction works just as well as preventive balloon dilation of the other coronary arteries, according to a new large study by researchers at Karolinska Institutet and others. The results are published in the New England Journal of Medicine.

Scientists at King’s have discovered a new cause for asthma that sparks hope for treatment that could prevent the life-threatening disease.

The breakthrough research by TATA memorial centre scientists who have developed a tablet which reduces side effects of cancer treatment and prevent resurgence or relapse of cancer said Dr Rajendra Badwe, Director of the Tata Memorial Centre in an interview with NDTV. The said tablet will be available at an affordable price of Rs. 100 a tablet.

Orchid Pharma, based in Chennai, India, has received approval by the United States Food and Drug Administration (USFDA) for its novel invention, ‘Enmetazobactam’. This development comes in close succession to the recent recommendation for approval by the European Medicines Agency (EMA). Enmetazobactam is the first completely invented-in-India Beta Lactamase Inhibitor.